Official Title
Evaluation of the Role of Sonoclot Signature in Assessment of Coagulopathy in Critically Ill COVID 19 Patients
Brief Summary

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

Status
Completed
Conditions
Coagulation Disorder
Interventions

Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA

studying coagulation disorders in COVID19 critically ill patients

Eligibility Criteria

Inclusion Criteria:

- COVID 19 critically ill patients

Exclusion Criteria:

- any critical illness not related to COVID 19

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Countries
Egypt
Locations

Assiut university
Assiut, Egypt

Sponsors / Collaborators
Assiut University
NCT Number
NCT04479280
MeSH Terms
Hemostatic Disorders
Blood Coagulation Disorders